MILLENNIUM PHARMACEUTICALS, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1993-01-01
- Employees
- 1K
- Market Cap
- -
A Study to Evaluate TAK-931 in Participants With Advanced Nonhematologic Tumors
- First Posted Date
- 2016-03-04
- Last Posted Date
- 2021-02-21
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 80
- Registration Number
- NCT02699749
A Study to Evaluate the Relative Bioavailability, Effect of Food, and Gastric Potential Hydrogen (pH) Modification on the Pharmacokinetics of TAK-117 (MLN1117) in Healthy Participants
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2015-12-09
- Last Posted Date
- 2018-01-08
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 54
- Registration Number
- NCT02625259
An Efficacy and Safety Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine in Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML) and Low-Blast Acute Myelogenous Leukemia (AML)
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2015-11-20
- Last Posted Date
- 2022-09-19
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 120
- Registration Number
- NCT02610777
- Locations
- 🇺🇸
Cleveland Clinic, Cleveland, Ohio, United States
🇺🇸Greenville Health System, Little Rock, Arkansas, United States
🇺🇸Johns Hopkins University, Baltimore, Maryland, United States
MLN1117 in Combination With Docetaxel, Paclitaxel, and Other Investigational Anticancer Agents to Treat Participants With Gastric and Gastroesophageal Adenocarcinoma
Phase 1
Terminated
- Conditions
- Interventions
- First Posted Date
- 2015-09-16
- Last Posted Date
- 2019-09-20
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT02551055
A Safety, Tolerability, and Pharmacokinetics Study of MLN0128 as a Single Agent and in Combination With Paclitaxel in Adults With Advanced Nonhematologic Malignancies
- First Posted Date
- 2015-04-09
- Last Posted Date
- 2020-02-28
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 61
- Registration Number
- NCT02412722
Docetaxel With or Without TAK-117 (MLN1117) in Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer
- First Posted Date
- 2015-03-19
- Last Posted Date
- 2018-02-07
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 14
- Registration Number
- NCT02393209
MLN0264 in Previously Treated Asian Participants With Advanced Gastrointestinal Carcinoma or Metastatic or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Guanylyl Cyclase C
Phase 1
Terminated
- Conditions
- Interventions
- First Posted Date
- 2015-03-18
- Last Posted Date
- 2017-03-29
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT02391038
Alisertib (MLN8237) in Combination With Weekly Paclitaxel in East Asian Patients With Advanced Solid Tumors
Phase 1
Terminated
- Conditions
- Interventions
- First Posted Date
- 2015-02-20
- Last Posted Date
- 2019-06-26
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 9
- Registration Number
- NCT02367352
A Study MLN2480 in Combination With MLN0128 or Alisertib, or Paclitaxel, or Cetuximab, or Irinotecan in Adult Participants With Advanced Nonhematologic Malignancies
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2014-12-30
- Last Posted Date
- 2020-02-25
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 81
- Registration Number
- NCT02327169
- Locations
- 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
A Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics of Alisertib in Participants With Advanced Solid Tumors or Relapsed/Refractory Lymphoma
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2014-10-08
- Last Posted Date
- 2019-09-20
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT02259010
© Copyright 2024. All Rights Reserved by MedPath